CDT Equity Secures Canadian Patent for AZD5904, Completing Global IP Coverage in Male Infertility

With Canadian patent grant now confirmed, CDT Equity Inc. has closed the final gap in its geographic IP coverage for AZD5904, a myeloperoxidase inhibitor originally licensed from AstraZeneca and repositioned for male infertility, a therapeutic area carrying no approved pharmacological treatments and an estimated annual market of USD $4.4 billion. For CDMOs and specialty manufacturers tracking early-stage licensing pipelines, the completion of this patent estate signals that formal partnering discussions are moving closer to term-sheet territory.

The Canadian grant follows approvals across all other key pharmaceutical target markets, and CDT has also filed a composition of matter application intended to extend the asset's IP runway beyond the use patent. AZD5904 carries an existing clinical safety package from its prior AstraZeneca development history, reducing the de-risking burden that typically falls on a licensing partner during early due diligence. That profile, combined with pre-clinical validation in male infertility, positions the asset as a relatively advanced candidate for a field where regulatory precedent is thin and 21 CFR Part 211-compliant manufacturing infrastructure remains largely unbuilt.

For QA and regulatory leads evaluating potential manufacturing partnerships in this space, the absence of a reference drug product in male infertility creates both process validation complexity and first-mover advantage. Any CDMO or specialty manufacturer entering a licensing arrangement for AZD5904 would be establishing the comparator, not benchmarking against one, a consideration that affects everything from analytical method development to stability protocol design under ICH Q10 quality system expectations.

CDT's Chief Scientific Officer, Dr. Joanne Holland, confirmed that partnering and future development discussions are ongoing, without specifying counterparties or timelines. The company's platform approach, which incorporates solid-form chemistry and asset repositioning, suggests that formulation optimization for AZD5904 may still be in scope before a licensing structure is finalised, a variable that prospective manufacturing partners should factor into capacity planning conversations.

The next measurable checkpoint will be whether CDT converts active partnering discussions into a disclosed licensing or co-development agreement, a step that would define the manufacturing scale, dosage form requirements, and regulatory filing strategy for AZD5904's first clinical programme in male infertility.

Source: CDT Equity Inc. via GlobeNewswire, 27 May 2026.